<DOC>
	<DOCNO>NCT00577031</DOCNO>
	<brief_summary>This single arm study evaluate efficacy safety first-line regimen Avastin XELOX ( oxaliplatin + Xeloda ) patient metastatic cancer colon rectum . Patients receive 21-day cycle treatment , comprise Avastin 7.5mg/kg iv day 1 , oxaliplatin 130mg/m2 iv day 1 , Xeloda 1000mg/m2 po twice daily day 1-14 , maximum 6 month . Patients stable disease complete partial response may continue Avastin therapy . The anticipated time study treatment disease progression , target sample size 100-500 individual .</brief_summary>
	<brief_title>OBELIX Study : A Study Avastin ( Bevacizumab ) Combination With XELOX Patients With Metastatic Cancer Colon Rectum .</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; locally advance metastatic colorectal cancer ; previous treatment chemotherapy metastatic disease ; least one measurable lesion . radiotherapy site within 4 week study ; untreated brain metastasis primary brain tumor ; clinically significant cardiovascular disease ; chronic daily treatment high dose aspirin ( &gt; 325 mg/day ) ; coexist malignancy malignancy diagnose within last 5 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>